2016 11th IDF-WPR Congress

BPM's DNlite technology has been favored by Boehringer Ingelheim, a large European pharmaceutical company, and applied in its third global clinical trial.  The corresponding results are appeared in 11th International Diabetes Federation Western Pacific Region Congress (11th IDF-WPR Congress) for the first time public.  In addition, cooperating with Division of Metabolism and Endocrinology of National Taiwan University Hospital and Pediatric Endocrinology of Mackay Hospital, there are three publications.  For both type 1 and type 2 diabetes patients, DNlite have contributed to early screening diabetic complications of renal risk, especially in tracking more than two years of type 2 diabetes patients and more observed to have the potential as an indicator of deterioration of renal function evaluation.


Topic of the IDF-WPR

DNlite application


Optimizing Diabetes Therapy Apply

Renal Efficacy Evaluation in MARLINA-T2D™ Trial


Diabetes Complications: Epidemiology and Biomarkers

DKD Progression Prediction in T2DM


Delay Diabetes Complication: What Can We Do?

Early Detection of DKD in T2DM


Novel Biomarkers for Diabetes

Validation of DNlite in T1DM